

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III DREAMM-7 trial yielded which of the following outcomes with belantamab mafodotin/bortezomib/dexamethasone in comparison to daratumumab/bortezomib/dexamethasone for patients with relapsed/refractory (R/R) multiple myeloma (MM) who had received at least 1 prior line of therapy?
 - a. No difference in overall survival (OS)
 - b. A numerical but nonsignificant trend in improved OS
 - c. A statistically significant improvement in OS
2. According to Phase III clinical trial data, belantamab mafodotin has led to a significant improvement in progression-free survival in comparison to standard therapy when used in combination with which of the following regimens for R/R MM?
 - a. Bortezomib/dexamethasone
 - b. Pomalidomide/dexamethasone
 - c. Both a and b
 - d. Neither a nor b
3. Which of the following drug types best describes the mechanism of action of linvoseltamab?
 - a. BCMA-targeted antibody-drug conjugate
 - b. CD3 x BCMA bispecific antibody
 - c. BCMA-targeted CAR T-cell therapy
 - d. CD3 x GPRC5D bispecific antibody
 - e. GPRC5D-targeted antibody-drug conjugate
4. Which of the following drug types best describes the mechanism of action of mezigdomide?
 - a. BCMA-targeted antibody-drug conjugate
 - b. SLAMF7 tyrosine kinase inhibitor
 - c. Proteasome inhibitor
 - d. CELMoD (cereblon E3 ligase modulator)
 - e. Selective inhibitor of nuclear transport
5. Which of the following descriptions best reflects the design of the EXCALIBER Maintenance trial?
 - a. A Phase I dose-ranging study evaluating iberdomide with dexamethasone as maintenance therapy for newly diagnosed, transplant-ineligible MM
 - b. A Phase II study evaluating iberdomide with lenalidomide as maintenance therapy after autologous stem cell transplant (ASCT) for newly diagnosed MM
 - c. A Phase III randomized study evaluating iberdomide versus lenalidomide as post-ASCT maintenance therapy for newly diagnosed MM